Zimbabwe has rejected a significant American health deal valued at 367 million US dollars (£272m) spanning five years due to the United States' demand for confidential information.
The decision came to light after a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa felt the agreement was "skewed".
A government spokesperson later clarified that the United States was seeking health data for research and profit while refused to share the resulting advantages from any future vaccines.
"We must now begin the challenging and unfortunate process of scaling back our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had donated over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further talks to secure a deal agreeable to both sides so the country's vital HIV treatment initiative can proceed.
Wider Context
Zimbabwe's decision comes after a similar case in Kenya, where a court halted a similar health funding agreement following concerns were raised about the safety of Kenyans' medical information.
After returning to the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the US government, but Trump claimed its expenditure was "inefficient" and his administration was seeking direct bilateral agreements to enhance transparency and accountability.
Based on reports, 16 African countries have so far signed similar health pacts, constituting over $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration might have yielded significant benefits for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment via US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, without any equivalent guarantee of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," Mangwana explained.
"In essence, our country would provide the basic resources for scientific discovery with no assurance that the end products would be available to our citizens if a new health crisis emerge."
Sovereignty and Global Health
He also noted that the American exit from the global health body and its push of bilateral deals were upending systems previously set up through the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This mechanism is designed to ensure that when a nation contributes its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
These objections over the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to further dialogue with our American counterparts on how subsequent co-operation might be designed in a way that honours the sovereignty and dignity of each country."
Health Experts Response
Medical experts expressed it understood the government's concerns, but recommended that negotiations need to persist since much of the nation's HIV programmes relied on foreign aid.
"In cases where specific concerns exist, including those relating to data governance or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," the group said.
The situation highlights the ongoing debate between accepting much-needed foreign assistance and protecting a country's data in an ever more data-driven world.